Physician profile
Alan D Harsch
NPI 1912948795
$1,711.31
in general payments reported to CMS, 2019-2025
10 companies · $416 in 2025
The $416 reported for 2025 was more than what 75% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $519 · 2024: $538 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $498.84 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $297.28 | 2022-2025 | Dupixent |
| Pharming Healthcare, INC. | $277.58 | 2023-2025 | Ruconest, Joenja |
| Amgen INC. | $261.80 | 2022-2025 | Tezspire |
| Genzyme Corporation | $117.29 | 2024-2025 | |
| Baxter Healthcare | $104.43 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Synclara Cough System |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Philips North America LLC | $42.37 | 2023-2024 | (Ak6) Vest Therapy |
| Electromed, INC. | $19.87 | 2024 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $17.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Harsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.